| Identification | Back Directory | [Name]
Pyrazolo[1,5-a]pyrimidine, 5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]-3-[4-(trifluoromethyl)-1H-pyrazol-1-yl]- | [CAS]
2353522-15-1 | [Synonyms]
Paltimatrectinib
Pyrazolo[1,5-a]pyrimidine, 5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]-3-[4-(trifluoromethyl)-1H-pyrazol-1-yl]- | [Molecular Formula]
C20H15F5N6 | [MOL File]
2353522-15-1.mol | [Molecular Weight]
434.37 |
| Chemical Properties | Back Directory | [density ]
1.56±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 25 mg/mL (57.55 mM; ultrasonic and warming and heat to 75°C) | [form ]
Solid | [pka]
0.37±0.40(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
Paltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC50 of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases[1]. | [IC 50]
TrkA | [storage]
Store at -20°C | [References]
[1] Kollol Pal, et al. 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer. WO2019118584A1. |
|
|